OR HB3799

Allows health care practitioners to treat patients with terminal diseases or severe chronic diseases using investigational drugs, biological products, or devices not yet approved by the FDA but currently in clinical trials

Requires patients to be Oregon residents, at least 18 years old, mentally capable, and acting voluntarily; patients must receive referrals from an attending physician and confirmation from a consulting physician before treatment

Provides liability protections for health care practitioners, facilities, professional organizations, and manufacturers/distributors who comply with the Act, except in cases of gross negligence

Patients must sign a witnessed form waiving liability and acknowledging that the treatment is experimental, may not be effective, may require out-of-pocket payment, and that insurers are not required to reimburse treatment costs or resulting adverse effects

Oregon Health Authority must annually review treatment records, collect data on outcomes, adverse effects, costs, and patient demographics, and submit statistical reports to the legislature by February 1 of each odd-numbered year